2020Annals of HepatologyOpen access

Hepatic and gastrointestinal manifestations of SARS-COV-2 infection (COVID-19)

Jorge Aquino-Matus, Iván López-Méndez, Eva Juárez-Hernández, Sofia Murua-Beltrán Gall, Jose D. Prieto-Nava, Paulo Castañeda-Méndez, Graciela Castro‐Narro, Misael Uribe

Open full text 1 citations

Abstract

Background and aim: Abnormal liver function tests (LFTs) and gastrointestinal (GI) symptoms have been reported up to 50% in patients with COVID-19, and in 5% they can precede respiratory symptoms The objective of this work is to describe the LFTs and GI symptoms of patients with COVID-19 and their association with admission to the intensive care unit (ICU) and mortality Material and Methods We conducted a retrospective, cross sectional, descriptive study, using files from patients with a positive Gen Finder COVID-19 test, admitted to Medica Sur Clinic and Foundation between March 13th through May 14th, 2020 We performed descriptive analysis of data and its association with clinical outcomes Results: A total of 108 patients with COVID-19 were identified;68 5% (n = 74) were men, the mean age was 53 ± 14 years and the body mass index was 28 6 ± 5 8 kg/m2 The most frequent comorbidity was hypertension with 24% (n = 26) The presence of comorbidities was associated with risk of ICU admission (OR 3 9 [95% CI 1 6-9 9], p = 0 002) The most frequent symptoms were cough (72 2%, n = 78), fever (69 4%, n = 75) and dyspnea (48 1%, n = 52) At least one abnormal LFT was present in 94% (n = 103) of patients at admission, the most frequent was LDH (88 9%, n = 96), AST and GGT (63%, n = 65), which are summarized in Table 1 Patients presented abnormal LFTs and respiratory symptoms in 48 1% (n = 52), while 16 6% (n = 18) presented abnormal LFTs without respiratory symptoms Among GI symptoms, 37% (n = 4) reported at least one, including diarrhea (28 7%, n = 31), hyporexia (9 3%, n = 10), nausea (8 3%, n = 9) or vomiting (4 6%, n = 5) Of patients admitted to the ICU (n = 39), 27 5% (n = 10) presented at least one GI symptom Mortality was 7 4% (n = 8) No associations were found between abnormal LFTs, GI symptoms, and outcomes of mortality and ICU admission Conclusions: In patients with COVID 19, the presence of metabolic comorbidities confers a higher risk of ICU admission, in contrast to abnormal LFTs and GI symptoms that were not associated with clinical outcomes Conflicts of interest: The authors have no conflicts of interest to declare

About this research paper

What this paper is about

Background and aim: Abnormal liver function tests (LFTs) and gastrointestinal (GI) symptoms have been reported up to 50% in patients with COVID-19, and in 5% they can precede respiratory symptoms The objective of this work is to describe the LFTs and GI symptoms of patients with COVID-19 and their association with admission to the intensive care unit (ICU) and mortality Material and Methods We conducted a retrospective, cross sectional, descriptive study, using files from patients with a positive Gen Finder COVID-19 test, admitted to Medica Sur Clinic and Foundation between March 13th through May 14th, 2020 We performed descriptive analysis of data and its association with clinical outcomes Results: A total of 108 patients with COVID-19 were identified;68 5% (n = 74) were men, the mean age was 53 ± 14 years and the body mass index was 28 6 ± 5 8 kg/m2 The most frequent comorbidity was hypertension with 24% (n = 26) The presence of comorbidities was associated with risk of ICU admission (OR 3 9 [95% CI 1 6-9 9], p = 0 002) The most frequent symptoms were cough (72 2%, n = 78), fever (69 4%, n = 75) and dyspnea (48 1%, n = 52) At least one abnormal LFT was present in 94% (n = 103) of patients at admission, the most frequent was LDH (88 9%, n = 96), AST and GGT (63%, n = 65), which are summarized in Table 1 Patients presented abnormal LFTs and respiratory symptoms in 48 1% (n = 52), while 16 6% (n = 18) presented abnormal LFTs without respiratory symptoms Among GI symptoms, 37% (n = 4) reported at least one, including diarrhea (28 7%, n = 31), hyporexia (9 3%, n = 10), nausea (8 3%, n = 9) or vomiting (4 6%, n = 5) Of patients admitted to the ICU (n = 39), 27 5% (n = 10) presented at least one GI symptom Mortality was 7 4% (n = 8) No associations were found between abnormal LFTs, GI symptoms, and outcomes of mortality and ICU admission Conclusions: In patients with COVID 19, the presence of metabolic comorbidities confers a higher risk of ICU admission, in contrast to abnormal LFTs and GI symptoms that were not associated with clinical outcomes Conflicts of interest: The authors have no conflicts of interest to declare

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Background and aim: Abnormal liver function tests (LFTs) and gastrointestinal (GI) symptoms have been reported up to 50% in patients with COVID-19, and in 5% they can precede respiratory symptoms The objective of this work is to describe the LFTs and GI symptoms of patients with COVID-19 and their association with admission to the intensive care unit (ICU) and mortality Material and Methods We conducted a retrospective, cross sectional, descriptive study, using files from patients with a positive Gen Finder COVID-19 test, admitted to Medica Sur Clinic and Foundation between March 13th through May 14th, 2020 We performed descriptive analysis of data and its association with clinical outcomes Results: A total of 108 patients with COVID-19 were identified;68 5% (n = 74) were men, the mean age was 53 ± 14 years and the body mass index was 28 6 ± 5 8 kg/m2 The most frequent comorbidity was hypertension with 24% (n = 26) The presence of comorbidities was associated with risk of ICU admission (OR 3 9 [95% CI 1 6-9 9], p = 0 002) The most frequent symptoms were cough (72 2%, n = 78), fever (69 4%, n = 75) and dyspnea (48 1%, n = 52) At least one abnormal LFT was present in 94% (n = 103) of patients at admission, the most frequent was LDH (88 9%, n = 96), AST and GGT (63%, n = 65), which are summarized in Table 1 Patients presented abnormal LFTs and respiratory symptoms in 48 1% (n = 52), while 16 6% (n = 18) presented abnormal LFTs without respiratory symptoms Among GI symptoms, 37% (n = 4) reported at least one, including diarrhea (28 7%, n = 31), hyporexia (9 3%, n = 10), nausea (8 3%, n = 9) or vomiting (4 6%, n = 5) Of patients admitted to the ICU (n = 39), 27 5% (n = 10) presented at least one GI symptom Mortality was 7 4% (n = 8) No associations were found between abnormal LFTs, GI symptoms, and outcomes of mortality and ICU admission Conclusions: In patients with COVID 19, the presence of metabolic comorbidities confers a higher risk of ICU admission, in contrast to abnormal LFTs and GI symptoms that were not associated with clinical outcomes Conflicts of interest: The authors have no conflicts of interest to declare

Key concepts: Medicine, Internal medicine, Comorbidity, Intensive care unit, Coronavirus disease 2019 (COVID-19), Gastroenterology, Body mass index, Retrospective cohort study

Related papers

Back to paper searchBrowse research topicsOriginal source
Hepatic and gastrointestinal manifestations of SARS-COV-2 infection (COVID-19) — Research Paper | ScholarLens